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Abstract: The production of magnetic nanoparticles of utmost quality for biomedical 
imaging requires several steps, from the synthesis of highly crystalline magnetic cores to 
the attachment of the different molecules on the surface. This last step probably plays the 
key role in the production of clinically useful nanomaterials. The attachment of the 
different biomolecules should be performed in a defined and controlled fashion, avoiding 
the random adsorption of the components that could lead to undesirable byproducts and  
ill-characterized surface composition. In this work, we review the process of creating new 
magnetic nanomaterials for imaging, particularly for the detection of atherosclerotic 
plaque, in vivo. Our focus will be in the different biofunctionalization techniques that we 
and several other groups have recently developed. Magnetic nanomaterial functionalization 
should be performed by chemoselective techniques. This approach will facilitate the 
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Superparamagnetic iron oxide nanoparticles (IONPs) are entering a new phase in the biomedical 
field, with a mushrooming spectrum of applications that no longer limits its clinical use [1]. For 
instance, oncological research has widely found an application of these nano-platform-based diagnosis 
and therapy tools, due to their specific features [2,3]. The situation for cardiovascular diseases is not 
that advanced yet; but, the research is quite intensive, and most researchers working in the field have 
realized the potential of applying nanotechnology to their work. This has translated into many results 
in conditions, like atherosclerotic plaque, stroke or myocardial infarction [4–8]. 
Figure 1. Steps in the synthesis of iron oxide nanoparticles (IONP) for preclinical 
atherosclerosis imaging. (A) Mixture of iron precursors and different surfactants in organic 
solvents; (B) Iron oxide nanoparticles in organic solvent; (C) Phase transfer to a  
water-based solution, in two steps or in a one-step phase transfer and functionalization (red 
arrow); (D) Functionalization of the nanoparticles for selective and/or multifunctional 
imaging; (E) Imaging of atherosclerotic plaque with iron oxide nanoparticles. EPR, 
enhanced permeability and retention. 
 
The interest in the application of these compounds in cardiovascular imaging and chemical probes, 
in general, is reflected in the number of reviews dealing with several aspects of the field. Our approach 
in this review is somehow different, and it is depicted in Figure 1. We will study the different steps 
allowing for the in vivo detection of atherosclerotic plaque. The first step is the combination of iron 
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precursors and surfactants, which includes the selection of the most appropriate combination of 
compounds and solvent to get nanoparticles with good crystallinity, magnetic and colloidal properties. 
Next in this process is to get water-stable and functionalized nanoparticles. This has been traditionally 
done in two steps, a phase transfer reaction and a second step with the attachment of the biomolecule. 
However, with the development of new approaches that perform chemical reactions over the initial 
organic surfactant, this process can be reduced to a single step in which the stabilization in water and 
the attachment of a biologically relevant molecule is done altogether. The final step is the preclinical 
application of the nanoparticles to an animal model of atherosclerosis. To get the selective 
accumulation of the nanoparticles inside the body, several strategies can be followed, e.g., macrophage 
targeting, plaque calcification, the angiogenesis process or by taking advantage of the enhanced 
permeability and retention (EPR) effect [9]. 
By studying the different chemical routes for the synthesis of homogeneous superparamagnetic and 
biofunctionalized IONPs and the biology behind atherosclerosis disease, a rational and focused 
strategy can be developed for the synthesis of clinically-relevant nanoparticles. 
2. Synthesis of Iron Oxide Superparamagnetic Nanoparticles 
Due to the relevance and wide spectrum of applications with IONPs, there has been a tremendous 
increase in the synthetic methodologies in the past few years. The most relevant approaches include 
methods, such as coprecipitation [10–12], thermal decomposition [13–15], sonolysis [16,17],  
sol-gel processes [18,19], spray and laser pyrolysis [20–22], hydrothermal and high temperature 
synthesis [23–26], nanoreactors, such as protein cages [27–29], vesicles [30], microemulsions [31,32] 
and microwave-assisted synthesis [33–38]. For the sake of simplicity, we will focus here only on the 
most interesting ones from the biomedical point of view, particularly the most common  
ones with a higher prevalence and projection: coprecipitation, thermal decomposition and  
microwave-assisted synthesis. 
2.1. Co-Precipitation Method 
One of the most employed methodologies for the synthesis of iron oxide nanoparticles for 
biomedical applications is the co-precipitation method. This process involves a reaction of the aqueous 
mixture of Fe2+/Fe3+ salt solutions with a base. Under these conditions, magnetite nanoparticles are 
formed by the aggregation of primary particles within a Fe(OH)2 gel. This methodology, developed by 
Massart et al., was carried out initially without the incorporation of any stabilizing molecule on the 
surface of the nanoparticles.[10] In this work, they reported the controlled preparation of IONPs 
through alkaline precipitation of FeCl3 and FeCl2. The magnetite (Fe3O4) particles formed were 
roughly spherical, with a diameter of 8 nm, measured by XRD. 
In this approach, magnetite is prepared by adding a base to an aqueous mixture of Fe2+ and Fe3+ 
salts in a 1:2 molar ratio. The overall reaction may be written as follows, leading to the precipitation of 
black magnetite [10]: 
Fe2+ + 2Fe3+ + 8OH− → Fe3O4 + 4H2O 
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In this reaction, a complete precipitation of Fe3O4 should be expected at pH 9, while maintaining a 
molar ratio of Fe3+:Fe2+ of 2:1. The reaction is performed under a non-oxidizing oxygen-free 
environment, by bubbling N2 in the reaction, something that also helps to reduce the final size of  
the nanoparticles [39]. 
A wide variety of parameters must be considered in this method in order to control size, magnetic 
characteristics and colloidal stability in the solution. Magnetization can vary drastically with synthesis 
variations even within particles of a similar size, due to the incorporation of impurities into the crystal 
structure and the involvement of surface effects [40,41]. Generally, magnetization saturation values of 
magnetite nanoparticles obtained by this method are in the range of 30–50 emu/g; lower than the 
90 emu/g reported for their bulk form [42,43]. In addition, the determining parameter in controlling 
their size is the pH, which must be adjusted in both the synthesis and purification steps. As a result, the 
production of narrowly dispersed particles remains a significant challenge in this method [44]. Other 
factors, like adjustment of the Fe3+:Fe2+ ratios, heating regimes and the coating-iron ratios must be 
strictly controlled [45,46]. 
After the initial development by Massart et al., the number of coatings that have been used vary 
from polymers [47–50], to dendrimers [51] and organic acids [52–54]. For example, adding increasing 
amounts of citrate ions in the Massart process allows for a decrease in the diameter of citrate-coated 
nanoparticles from 8 to 3 nm. Citrate chelates iron ions, preventing nucleation, and at the same time, 
the adsorption of citrate on the nuclei produces hydrolysis, inhibiting the growth of the nuclei [55]. 
The main advantage of the co-precipitation process is that a large amount of water-stable 
nanoparticles are obtained. However, the control of particle size distribution is limited, because only 
kinetic factors are controlling the growth of the crystal. This leads to the synthesis of somehow 
heterogeneous samples in terms of size and shape. Another problem that can be found with this 
approach is the weak attachment of the surfactant to the surface and the reduced number of functional 
groups that can be found on the surface, all of this complicating the final functionalization for 
biomedical applications. 
2.2. Thermal Decomposition of Organic Precursors 
High temperature decomposition of iron organic precursor mixed with surfactants in organic 
solvents is progressively becoming the standard way for the preparation of IONPs. This method yields 
nanoparticles of a narrow size distribution, good crystallinity and high magnetization saturation values 
(Figure 2) [56]. The first synthesis introduced by Aliviastos et al. reported the injection of  
FeCup3 (Cup:N-nitrosophenylhydroxylamine) solutions in hot trioctylamine resulting in nanoparticles 
of 4 to 10 nm average diameters as a function of the temperature (250 °C to 300 °C) and the quantity 
of iron precursor added. A second method consisted of the preparation of iron nanoparticles by the 
injection of the organic Fe(CO)5 precursor in the surfactant mixture followed by an in situ oxidation 
phase to produce highly crystalline and monodispersed maghemite nanoparticles with sizes from 4 to 
16 nm [57–59]. Although the hot injection technique guarantees instant nucleation and homogenous 
growth for an optimal quality of the nanoparticles, it also presents drawbacks mainly related to safety 
and toxicological issues [60]. Heating up processes were then proposed with iron oleate, an 
intermediate prepared from FeCl3 and the mechanisms of crystallizations studied [61,62]. In 2002, 
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Sun et al. described a single step synthesis using iron acetylacetonate thermal degradation by 
progressive heating in diphenyl ether in the presence of alcohol, oleylamine and oleic acid  
surfactants [13,63]. The magnetite nanoparticles prepared with this method have dimensions in the 3 to 
20 nm range adjusted by a control of the reaction time or the amount of the low complexing reactants. 
FeO(OH) has also been proposed as an organic precursor for thermal synthesis to produce 
nanoparticles with sizes below 20 nm [64]. A summary of the most relevant approaches using the 
thermal decomposition of organic precursors can be found in Table 1. 
Figure 2. TEM images of 16-nm IONPs synthesized by the decomposition of organic 
precursors:  (A) a monolayer assembly; (B) a multilayer assembly; (C) High Resolution 
Transmission Electron Microscopy (HRTEM) image of a single Fe3O4 nanoparticle. 
Reproduced with permission from [13]. Copyright 2002, American Chemical Society. 
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Table 1. Main aspects of the synthesis of superparamagnetic iron oxide nanoparticles by thermal decomposition methods.  
PAA, polyacrylic acid. 
Iron precursors Surfactant Solvent T/°C Shape and Size Refs. 
FeCup3 Octylamine Trioctylamine 250–300 °C 4–10 nm [15] 
Fe(CO)5 Oleic acid Dioctyl ether 300 °C 4–16 nm [57] 
Fe(CO)5 tri-n-octylphosphine 
oxide (TOPO) 
Ortho-dichlorobenzene 180 °C 12 nm variation possible 
(diamond, triangle, spherical) 
[67] 
Fe(acac)3 Oleic acid 
Oleyl amine 
Phenyl ether 
or benzyl ether 
259–298 °C <20 nm 
Seed mediated growth: 20 nm  
[13] 
[63] 
Fe(oleate)3 from FeCl3 
and sodium oleate 
Oleic acid  1hexadecane or 
trioctylamine or (2 more) 
274–365 °C 5–22 nm [61] 







245 °C 5 nm 











12–30 nm [71] 
[72] 
Fe(acac)3 PVP N-vinyl-2-pyrrolidone 200 °C 4–40 nm [73] 
FeCl3 PAA  diethylenglycol 220 °C 3–12 nm [74] 
The size and morphology of the nanoparticles are the result of the growth mechanism during the thermal decomposition method. We will focus in this 
review only on the influence of the different reaction conditions; further details of the growth mechanism models have been reviewed in several 
occasions, like in Gao et al [65]. For instance, the time of reaction of the growth phase clearly regulates the size [66]. Furthermore, nanoparticles prepared 
with higher temperatures lead to larger sizes; successfully employed by heating with various solvents of high boiling points [61]. Another critical variable 
in the structural features of the nanoparticles is the surfactant or mixture used for emulsifying the systems and to control nucleation. It was observed that 
the size of the nanoparticles is inversely proportional to the tendency of the surfactant to coordinate with the iron atom [67,68]. Thus, common methods 
often control the size of the nanoparticles by the addition of a low complexing surfactant [68]. Sizes can also be modified depending on the molar 
proportion, Fe:surfactant [64]. Finally, it was shown that the affinity properties of the solvent for iron can play a major role in this process [69]. Although 
few studies also assessed the influence of the organic iron precursors, preliminary observations show that a narrower and controlled particle size 
distribution is favored with a specific iron intermediate complex before the generation of the cores [70]. 
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Shape-controlled synthesis of iron oxide nanoparticles with this method can be performed under 
thermodynamic or kinetic control. Thermodynamic control is the key aspect when working with a low 
concentration of precursors, yielding spherical nanoparticles to minimize the surface energy. When 
working at high concentration conditions, kinetic control will lead to the formation of particles with 
other morphologies, such as cubic or elongated particles [62,69,75]. 
The above described thermal decomposition synthesis is a powerful method to produce IONPs of 
higher quality than the ones prepared by the aqueous routes [68]. One drawback of this approach is 
that the hydrophobic character of the nanoparticles makes compulsory a second step to transfer the 
IONPs to water. This necessity of rendering hydrophilic nanomaterials has boosted the appearance of 
new efficient chemical routes for the functionalization of nanoparticles. 
Before the use of these new alternatives, the efforts focused on the modification of the thermal 
decomposition method with hydrophilic surfactants and/or polar solvents to provide hydrophilic 
nanoparticles in a one-pot synthesis route. Gao’s group first reported the use of 2-pyrrolidone, a strong 
polar organic solvent [14]. In the first attempt, 2-pyrrolidone had also the role of surfactant with 
Fe(acac)3 as the iron precursor. These nanoparticles of roughly 5 nm were hydrophilic, but with poor 
stability, being stable under acidic or alkaline conditions, which provides optimum electrostatic 
repulsion, but showed aggregation at neutral pH conditions. This method was assessed also with 
FeCl3·6H2O as a precursor to obtain nanoparticles with an average size between 4 nm and 60 nm [76]. 
In order to synthesize nanoparticles stable in physiological solutions, mono- or di-carboxylic-
terminated poly(ethylene glycol) (PEG) polymers were introduced as the surfactant [71,72]. The 
amphiphilic character of this PEG coating confers on iron oxide nanoparticles’ important properties, 
such as high stability and solubility in different media [14]. Moreover, di-substituted carboxylic 
polymers have the advantage of showing a reactive group on the surface for further functionalization. 
These results opened a range of new studies assessing others polar organic solvents and surfactants, 
such as polyacrylic acid (PAA), N-vinyl-2-pyrrolidone, glycols or diphenyl oxide [73,74,77,78]. 
2.3. Microwave-Assisted Synthesis 
The use of microwaves in inorganic chemistry goes back to the 1970s and in organic chemistry to 
the 1980s. Although slow at the initial stages, the utilization of microwaves in chemical synthesis 
processes boosted from the mid-1990s. The main reasons for this increase included the availability of 
commercial equipment, the short reaction times and the expanded reaction range that is offered by 
microwave-assisted synthesis. These features make this approach particularly suited for the increased 
demands in industry. 
In general, most of the synthetic reactions to obtain IONPs include heating through traditional heat 
transfer equipment, such as oil baths, sand baths and heating jackets. These heating techniques are, 
however, rather slow, and a temperature gradient can develop within the sample, leading to local 
overheating spots. All these parameters may have an important effect both in the nucleation and 
growing steps of the synthesis. A fundamental aspect of the microwave approach is the dielectric 
heating; under these conditions, the energy is introduced into the reactor remotely. The microwave 
radiation passes through the walls of the vessel and heats only the reactants and solvent and not the 
reaction vessel itself. In modern pressurized equipment, the temperature increase is uniform 
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throughout the sample and facilitates heating far above the conventional boiling point of the solvent. 
All these features allow for the synthesis of IONPs with greater control/reproducibility of size and 
dispersity, as well as enhanced crystallinity. 
The characteristics we just highlighted are attracting the attention of many scientists working in the 
synthesis of nanoparticles. Currently, there are examples in the literature of the use of microwaves for 
the synthesis of maghemite nanoparticles [33–35], mixed maghemite and magnetite nanoparticles [36] 
and pure magnetite [38]. Due to the novelty of the approach, most of the recent publications focused 
more on the synthesis of the nanoparticle core and rather poorly on the colloidal stability of the 
synthesized nanoparticles in water. This is gradually changing, and there are examples already using 
PEG and dextran as surfactants for biomedical applications [24,79,80]. Considering these data, it is not 
difficult to foresee in the near future a field where the utilization of microwaves for the synthesis of 
IONPs will be of paramount importance; for example, in the synthesis of dual PET/MRI nanoparticles, 
where not only the quality of the nanoparticles is important, but also the rapid incorporation of the 
radioisotope, particularly with those of reduced half-life isotopes (18F and 68Ga) [81]. The synthesis of 
this type of nanoparticles would be a clear improvement in comparison with traditional chelator-based 
compounds from the point of view of toxicity, no transmetallation in vivo and a much better 
biodistribution, provided the surface of the nanoparticles is properly functionalized [82]. 
3. Biofunctionalization of Iron Oxide Nanoparticles 
When developing nanoparticles for biomedical or cardiovascular applications, the key point is the 
functionalization of the nanoparticles’ surface. Ideally, the functionalization should provide 
nanoparticles with very good colloidal stability in the usual conditions for in vivo administration  
(i.e., 0.9% NaCl, PBS, etc.) and provide as many as possible functional groups that can be employed 
for the attachment of biomolecules. 
The approach is different depending on the hydrophilic character of the initial IONPs. For those 
obtained by the coprecipitation method, the next step after the synthesis is the attachment of the 
biomolecule of interest. This sometimes can be a problem, since the number of functional groups on 
the surface is not that high. Since the IONPs obtained by thermal decomposition are usually of superior 
quality, we will focus this section on the functionalization of these particles. 
Traditionally, for the stabilization of the hydrophobic nanoparticles synthesized by thermal 
decomposition, there were two main approaches: the micelle-like approach and the ligand exchange. 
Recently, a new approach has been developed by our group based on the direct chemical modification 
of the organic surfactant; something that presents a number of advantages [83–86]. 
3.1. Ligand Exchange 
The ligand exchange approach is based on a mixture of hydrophobic IONPs with a very high 
concentration of the hydrophilic molecule. In such conditions, the hydrophilic ligand eventually 
displaces the hydrophobic surfactant, due to its affinity towards IONPs surface, thus yielding aqueous 
stable nanoparticles [87,88]. The most remarkable aspects of this approach are the simplicity and 
versatility, due to the enormous number of hydrophilic ligands that can be used for this purpose, like 
carboxylates, phosphates, polymers and inorganic materials (Table 2) [89–94]. However, this approach 
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also presents some disadvantages. One of them is the degree of exchange. If this is not high, the 
surface of the nanoparticle will contain hydrophobic moieties, leading to stabilization problems and, 
most importantly, to a significant reduction in the number of reactive functional groups for  
further functionalization [95]. 
Table 2. Summary of the main properties for the most common ligand-exchange protocols. 
DMSA, dimercaptosuccinic acid; PAMAM, poly(amido)amine; PAH, poly(allylamine). 
Ligand TEM (nm) DLS 1 (nm) r2 (mM
−1s−1) Ref. 
DMSA 9.0 ± 2.0 65.0 ± 5.0 317 [103] 
Citric acid 4.0 ± 0.5 8.6 ± 1.0 33 [56] 
1-mercapto-11-undecanoic acid  10.0 ± 3.0 170.0 ± 50.0 n.a. [104] 
2-bromo-2-methylpropionic acid 8.0 ± 1.0 n.a. n.a. [105] 
PEG-SiMe3 8.4 ± 1.5 12.2 ± 2.7 n.a. [98] 
NH2-SiMe3 8.7 ± 1.3 14.4 ± 2.8 n.a. [98] 
COOH-SiMe3 8.2 ± 1.2 13.5 ± 2.0 n.a. [98] 
Hydroxyethylenebisphosphonate 5.0 ± 1.5 15.2 ± 2.5 122 [101] 
Stilbenephosphonate 6.0 ± 0.5 39.0 ± 5.0 n.a. [106] 
PMIDA 2 5.0 ± 0.5 62.0 ± 3.0 n.a. [107] 
PAMAM 5.0 ± 2.0 90.0 ± 20.0 79 [108] 
Melanin-Dopamine 10.0 ± 2.0 n.a. 114 [109] 
PAA-PAH 11.0 ± 2.0 60.0 ± 10.0 n.a. [110] 
PNIPAM-b-PNIPAM 3 15.0 ± 3.0 60.0 ± 4.0 n.a. [111] 
DPA 4-PEG-COOH 9.0 ± 1.0 40.0 ± 2.0 n.a. [112] 
1 DLS: Dynamic Light Scattering; 2 PMIDA: N-phosphonomethyl iminodiacetic acid;  
3 PNIPAM: Poly(N-isopropylacrylamide); 4 DPA: methacrylate-co-2-(diisopropylamino)ethyl methacrylate. 
In general, the ligands utilized in this approach can be classified as small organic molecules and 
large polymeric compounds, such as dimercaptosuccinic acid (DMSA). This ligand, due to the 
carboxylic groups, shows a high affinity towards the IONP surface, thus providing high stability in 
aqueous media and enough free functional groups for further biomolecule conjugation with many 
applications [77,96,97]. DMSA-nanoparticles, with a small hydrodynamic size (less than 50 nm) and 
very good magnetic properties, can be obtained with this approach. These nanoparticles can be 
employed, for instance, for MRI and also drug delivery. Citric acid is another carboxylic-based ligand 
for the ligand exchange approach of common use in this very field. This acid may be adsorbed on the 
surface of the magnetite nanoparticles via one of the two carboxylate groups, depending on steric 
hindrance and the curvature of the surface. This leaves at least one of these functional groups exposed 
to the solvent, which should be responsible for making the surface negatively charged  
and hydrophilic [56]. 
Another kind of ligand with good properties for the exchange approach are silanes (Figure 3). These 
compounds present the general chemical formula, X-(CH2)n-SiR3, where SiR3 is the anchor group 
having good affinity for the surface of the nanoparticle, (CH2)n is the hydrophobic chain and X is the 
headgroup providing the hydrophilicity. Further surface modifications are possible depending on the X 
group [98]. The efficiency of ligand exchange reactions with silanes depends on various factors, like 
the concentration of the silicon tetrahydride, the reaction times and the presence of a catalyst [99]. 
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Although ligand exchange is a straightforward method and these factors can be easily controlled, the 
method with silanes shows poor reproducibility [100]. Other small molecules that have been used in 
this approach are phosphonates, of several compositions [101,102]. 
The utilization of large polymeric compounds for the exchange approach includes dendrimers, 
polyacrylic acid and PEG. In the case of dendrimers, the most common of these molecules in 
biomedicine, poly(amido)amine (PAMAM), is also the most commonly used for the functionalization 
of IONPs. These dendrimers have been conjugated with targeting ligands, imaging moieties and drug 
molecules for its application in cancer therapy [108,113,114]. Moreover, poly(amido)amine IONPs are 
a suitable platform for further functionalization to increase the circulation time of the nanoparticles in 
blood [51]. These macromolecules are obtained via conventional organic synthesis. In this regard, 
maghemite nanoparticles with uniform and monodisperse sizes were functionalized with dopamine, 
showing good aqueous stabilization [109]. 
Figure 3. Structure of common silane-based molecules for the ligand exchange approach. 
 
Polyelectrolytes, such as poly(acrylic acid) (PAA) and poly(allylamine) (PAH), are employed to 
replace the original hydrophobic ligands on the surface of iron oxide nanoparticles. These polymers 
need high temperature in ligand exchange reactions with IONPs. Therefore, polar solvents with a high 
boiling point, like diethylene glycol, are commonly used. Moreover, diethylene glycol has high 
miscibility in both aqueous and typical organic solvents and high power to dissolve polyelectrolytes, 
providing good features for this type of ligand exchange reaction with polymers at high temperature 
(>240 °C). In the case of PAA-PAH, nanoparticles, with a narrow core size distribution, stability in 
water and good magnetic properties, are obtained in a short reaction time [110]. 
As we have mentioned before, nanoparticle PEGylation with chains of different molecular weight, 
is well established to optimize the stabilization of nanoparticles and to prolong their circulation time in 
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blood after administration [115–117]. Regarding the utilization of this polymer in the ligand exchange 
approach, one of the best examples is the use of DPA-PEG-COOH (DPA: methacrylate-co-2-
(diisopropylamino)ethyl methacrylate), a synthetic compound produced from polyethylene glycol 
diacid (HOOC-PEG-COOH), in which one of the acid groups reacts with the terminal free amine of 
dopamine through the conventional EDC/NHS (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-
Hydroxysuccinimide) reaction obtaining DPA-PEG-COOH. After a ligand exchange reaction among 
DPA-PEG-COOH and oleic acid nanoparticles, water stable nanoparticles are achieved, even with 
different length chains of PEG. These nanoparticles have proven to have much less uptake by 
macrophages, indicating that these can evade recognition from these cells of the immune system [112]. 
3.2. Micelle-Like Approach 
Figure 4. Micelle approach for PAMAM-C12 coating of the oleic acid-capped iron oxide 
nanoparticles. Reproduced with permission from [142]. Copyright 2013, American 
Chemical Society. 
 
The utilization of amphiphilic structures for the stabilization and functionalization of IONPs is a 
second approach usually selected when synthesizing these compounds [118–122]. This method takes 
advantage of the structure of these amphiphilic molecules. The formation of weak van der Waals 
interactions between the hydrophobic part of these molecules and the organic tail of the nanoparticle 
coating, to minimize the interaction with water, produces very stable nanoparticles with excellent 
reproducibility (Figure 4). Furthermore, the possibility of a previous modification on the amphiphilic 
molecule allows for the stabilization and functionalization of the IONPs to be carried out in a single 
step, although this opportunity has not been fully addressed. To obtain such micelle-like structures, 
usually, the first option is to use a polymeric amphiphilic compound. The hydrophobic structure is 
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inserted between the hydrophobic chains of the surfactant/ligand adsorbed on the nanoparticle, while 
the hydrophilic part stands around the outer surface to assure the dispersion of the IONPs in biological 
media. Many kinds of polymers have been assessed, like pluronic [123–126], poly(maleic anhydride 
alt-1-tetradecene) [127], cyclodextrins [128], PEG-phospholipids conjugates [129,130] or other 
triblock polymers [131–133]. Other advantages of the method are the possibility of further crosslinking 
for better stabilization or encapsulation of small hydrophobic drugs in the hydrophobic bilayer that is 
created (as well as small organic fluorescent molecules). The final stability of the structure depends 
mainly on the nature of the polymers, i.e., amphiphilic balance, molecular weight, length of the chains 
or conformation [131]. 
To achieve the insertion of the polymers, several methods are possible, such as reverse 
evaporation [134,135], progressive increase of the solvent polarity [131] or nanoemulsion [136]. The 
encapsulation of hydrophobic nanoparticles in polymeric micelles [137] is very similar to the insertion 
option. Many examples are in the bibliography using diblock polymers, such as polylactide-b-
poly(ethylene-maleimide) [122,138], poly(styrene-block-acrylic acid) [131], poly(e-caprolactone)-b-
poly(ethylene glycol) [139,140] or dendrimers [141]. 
Control of self-assembly structures can be achieved from micelles to vesicles, based on the nature 
of the solvent used and other conditions [133]. Liposomes are another important structures based on 
amphiphilic compounds. Liposomes are vesicles composed of a lipid bilayer, and a very important 
platform for drug delivery and imaging applications [143]. To explain in detail the utilization of 
liposomes in general or their application in the synthesis of iron oxide nanoparticles, one will need 
another review, so we refer the reader to other sources already dealing with this aspect in detail, 
particularly those by Torchilin et al. in 2005 and Alen et al. in 2013 [142–147]. Here, we will only 
mention one work, especially relevant for the topic covered in this review, by Fayad and Mulder et al. 
(Figure 5) [148]. In this work, an HDL-like nanoparticle (HDL, high density lipoprotein) was 
developed with multimodal imaging properties, by including additional labels in the corona of the 
particles, such as iron oxide, Au and quantum dots. The in vitro and in vivo characterization of these 
particles demonstrated that they mimic many of the properties of the native HDL and, therefore, could 
be used for in vivo imaging of atherosclerotic plaque. 
Figure 5. Schematic structure and TEM imaging of HDL-iron oxide nanoparticles. 
Adapted with permission from [149]. Copyright 2008, American Chemical Society. 
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3.3. Chemical Modification of the Surfactant 
One of the new approaches that we review is based on the direct chemical modification of the 
surfactant, usually oleic acid. The ligand exchange method is based on the partial replacement of the 
oleic acid, whilst the micelle approach focuses on keeping it, but hidden below at least under a layer of 
the amphiphilic molecules. The chemical modification approach is based instead on performing 
organic reactions over the oleic acid. The final intention of this method is to bring all organic 
chemistry tools for the synthesis and functionalization of hydrophilic molecules. Although different 
alternatives can be foreseen, the most logical one is to perform chemistry in the functional group of 
oleic acid that is not involved in the surface binding of the nanoparticles: the carbon-carbon double 
bond. So far, there are two strategies that have been followed in this approach (Figure 6).  
Figure 6. Direct chemical modification of the surfactant for oleic acid-coated IONPs, by 
(A) oxidation of the double bond and (B) olefin metathesis by the use of Hoveyda-Grubbs 
2nd generation catalyst. 
 
We have demonstrated this approach for the first time in iron oxide nanoparticles, by using the very 
well-known double-bond oxidation with KMnO4 to generate a carboxylic group (Figure 6A). It is 
known that under these conditions, the permanganate ion forms a complex with the double bond that 
can be hydrolyzed in both acidic and basic pH. Under these conditions, IONPs were obtained with a 
40 nm mean diameter, a zeta potential of −46 mV and good magnetic (Ms = 77 emu/g Fe) and 
relaxometric properties (r1 and r2 are 4 s
−1 mm−1 and 115 s−1 mm−1). The reaction is performed in a 
two-phase system, a mixture of organic solvent, where the oleic acid nanoparticles are dispersed, and 
an aqueous phase, where the KMnO4 is soluble and where the IONPs are eventually dispersed. In this 
procedure, a phase-transfer catalyst is used to get enough concentration of the MnO4
− ion in the 
organic phase. The best results are obtained usually with trimethylbenzylammonium chloride. 
This modification renders water-stable particles and, at the same time, also, a functional group 
ready for the further attachment of biomolecules, from small organic molecules to dyes and 
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proteins [84,85] (Figure 7). Two of the most remarkable features of these modifications are that the 
nanoparticle is always protected by a layer of surfactant, thus minimizing the aggregation and that, by 
using an excess of the oxidant, a complete transformation of the oleic acid is achieved, as we 
demonstrated using magnetic resonance spectroscopy, mass spectrometry and infrared. This is a very 
important difference compared to the previous methods. By removing all oleic acid from the surface, 
more stable nanoparticles and less toxicity problems are expected. The same is true for further 
functionalization, since this approach allows for strong covalent interaction that, at no point, exposes 
the core of the nanoparticle [83,150]. 
Figure 7. Synthesis of multifunctional IONPs by the direct chemical modification of oleic 
acid. The attachment of allergen Phl p5a and a fluorophore, via biotin-streptavidin 
interaction, was done by amide formation with the carboxylic groups generated. TEM 
image of the final IONPs (bottom left). Immunogenicity of the synthesized nanoparticles 
compared to non-functionalized particles, grass pollen extract and pure protein (bottom 
right). Reproduced from [87]. Copyright 2012, John Wiley & Sons, Ltd. 
 
A second recent initiative is the direct modification of oleic acid using another well-known reaction 
in organic chemistry, the olefin cross-metathesis. The idea behind this is to take advantage of the 
functional group in the oleic acid. However, with the olefin metathesis option, we can go one step 
further. Since it is possible to incorporate a terminal olefin in many proteins and biomolecules, it can 
Nanomaterials 2014, 4 422 
 
 
be utilized for, in a single step, transferring the nanoparticles to water and providing specificity for 
biomedical applications [86,149,151]. Using this method, biofunctionalized IONPs are obtained again 
in two steps, but with better physicochemical properties. 
4. Application to Atherosclerotic Plaque 
Atherosclerosis is an inflammatory pathology of the blood vessel wall in which plaque builds up 
inside the arteries [152–156]. Plaque is mainly made up of lipids, cholesterol, calcium, macrophages 
and several substances found in the blood. Over time, plaque hardens and narrows the arteries, limiting 
the flow of oxygen-rich blood to the organs. 
During the atherothrombotic plaque formation, relevant events take place: inflammation, deposition 
of cholesterol, extracellular matrix (ECM) development and thrombosis [157–159]. Characteristics of 
atherosclerosis are the presence of fibrous and lipid-rich elements in vessel walls of arteries (coronary, 
carotid and aorta as the most common injured arteries). During the course of the pathology, myeloid 
cells de-stabilize the plaque, causing it to rupture [160]. Most of the damage occurs when plaques 
become fragile and rupture. Plaques that rupture cause the formation of blood clots that can block 
blood flow or break off and travel to another part of the body. Monocytes are infiltrated during early 
damage in the arterial wall and, in combination with macrophages, promote the inflammatory process. 
After activation of macrophages from monocytes in the sub-endothelial space, the ingestion of high 
amounts of lipids by the activated macrophages triggers the origin of foam cells. The accumulation of 
lipid cores by foam cells activated macrophages and necrotic cells, leading to the migration of smooth 
muscle cells to intima, forming the fibrous cap over the damage (Figure 8). These inflammatory 
events’ expression, accompanied with the delivery of proteolytic enzymes (metalloproteinases, 
cysteinyl cathepsins), which catabolize the extracellular matrix of fibrous cap in plaques, are 
responsible for plaque instability [161]. When this fibrous cap becomes thin, the plaque vulnerability 
risk is increased [152]. The complete mechanism explaining plaque instability and proneness to 
rupture is unknown yet [156]. 
4.1. Molecular Imaging in Atherosclerosis 
One of the main issues of an atherosclerotic lesion is that it develops slowly over decades, being 
finally identified at advanced states of the pathology [155]. One of the main goals in the  
utilization of molecular imaging in atherosclerosis is the possibility of early diagnosis, at a  
subclinical point [162,163]. 
Current approaches in atherosclerotic plaque imaging are mainly based on molecular imaging 
approaches by the targeting of biomolecules involved in the lesion progression. Macrophages are one 
of the most utilized targets in molecular imaging, due to their role during inflammation [152,156,163]. 
However, there are important biochemical targets that are indicative of plaque development,  
such as metalloproteinases, LDL-oxidized, calcium vesicles or receptors involved in 
neoangiogenesis [152,155,156]. Molecules involved in plaque rupture, like metalloproteinases 
(MMPs) and cathepsins, are highly recommended as molecular imaging targets. 
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Figure 8. Evolution of atherosclerosis disease and the main targets at each step, according 
to the American Heart Assocciation (AHA). Reproduced with permission from [158]. 
Copyright 2008, Nature Publishing Group. 
 
4.2. Iron Oxide Nanoparticles in Atherosclerosis Imaging 
The use of IONPs for atherosclerosis targeting makes use of the principal markers of the disease, 
such as MMPs, angiogenesis, activated platelets, cell adhesion molecules, apoptosis markers and fibrin 
markers. The first results with IONPs as a platform for molecular imaging in this context comes from 
the rapid uptake by the macrophages of the immune system [164–168]. Systematic evaluation of MRI 
with IONP as a contrast agent in carotid atheroma confirmed that the optimal signal intensity was 
achieved 24–36 h after i.v. (Intravenous) administration. In 2000, it was demonstrated that there is a 
spontaneous phagocytic uptake of superparamagnetic iron oxide nanoparticles by macrophage 
populations in atherosclerotic plaque [164,169]. There are numerous examples showing the feasibility 
of atherosclerosis imaging by the non-specific labeling of macrophages [162,163,170]. This has been 
done, for example, in humans, with IONPs synthesized by the coprecipitation approach and coated 
with dextran [168]. This study showed that the nanoparticles accumulate predominantly in 
macrophages in ruptured and rupture-prone human atherosclerotic lesions, inducing significant signal 
changes in the in vivo T2*w fast gradient echo MRI. Similar results were obtained later, also in 
humans, with the same type of nanoparticles in the imaging of carotid atheroma. The nanoparticles 
accumulated in macrophages of seven out of eight patients, demonstrating areas of MRI signal 
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reduction that correspond to IONPs/macrophage-positive histological sections. The MRI signal change 
was obtained between 24 h and 36 h after injection and was still evident up to 96 h after infusion. The 
explanation of how the IONPs are phagocytized by macrophages and end up in the plaque is related to 
the endothelial dysfunction theory. Plasma components are accumulated in the sub-endothelial space, 
allowing the progression of arterial wall inflammation. Low-density lipoproteins (LDL) are 
accumulated in their oxidized form and then phagocytized by macrophages. Finally, they form foam 
cells. The main similarity between LDL and IONPs are the diameter size (15–25 nm) and capability of 
accumulation in atheroma plaque with high macrophage activity [170]. Pharmacokinetics and the 
specific biodistribution of the probes based on IONPs depends on the particle size, as well as on the 
charge and surface properties [152,156,170,171]. Smaller particles are less efficiently uptaken than 
larger particles in the case of phagocytic cells. 
Another important option for the use of IONPs in atherosclerosis is the binding of specific ligands 
on the surface of the particles to increase selectivity. This has been done also for the labeling of 
macrophages; for example, with the binding of the PP1 LSLERFLRCWSDAPAK peptide that binds to 
SR-A receptors. These belong to the scavenger receptor family, which has an important role during 
foam cell formation and consequent activation. Increased expression of these receptors has been 
reported in foam cells during atherosclerotic damage and vascular smooth muscle cells (VSMCs) after 
plaque inflammation events [163,172]. It is possible to conjugate this ligand to the IONPs in order to 
increase nanoparticle uptake. A significant increment of this PP1-conjugated IONPs in vitro using 
plaque-associated macrophages and VSMCs was reported [172]. Similar results of nanoparticle 
accumulations were obtained by contrast-based MRI in atherosclerotic plaque lesions with humanized 
models using Western-type diet-fed LDLR−/− with human SR-AI, and in aged models with  
ApoE−/− mice [163]. 
Other important targets are cell adhesion molecules. Among them, due to its strict temporal and 
spatial expression/regulation, VCAM-1 has received most of the attention. There are several studies 
involving ligand-conjugated IONPs for MRI of endothelial adhesion molecules (VCAM-1 and  
P-selectin) [173,174]. IONPs have been conjugated with VCAM-1 internalizing peptides, identified by 
phage display. It has been reported that they are accumulated by cells with upregulated expression of 
VCAM-1, being specific for activated endothelium [153,156,173,174]. With the same aim of 
monitoring these proteins, IONPs could be also conjugated to specific moieties, like MHC-I peptides 
and VCAM-1 antibodies [156]. Another possible candidate is P-selectin, which is overexpressed on 
pathologically activated endothelium surfaces and activated platelets during atherosclerosis initiation, 
progression, rupture and thrombosis [175]. This marker has in fact been used for the synthesis of 
IONPs conjugated to an antihuman P-selectin antibody (VH10). The nanoparticles were validated in a 
model with ApoE−/− mice using a bimodal magnetofluorescent agent, for MRI and optical imaging of 
an inducible P-selectin expression in human activated platelets involved in the early stages of 
atherosclerosis [176]. Apoptosis is another event during plaque destabilization that has been used for 
the selective accumulation of IONPs in the atheroma lesion by the attachment of Annexin V in the 
surface of these nanoparticles. It is known that this protein has a high binding affinity for 
phosphatidylserine residues, translocated to the outer leaflet of the plasma membrane in apoptotic 
cells. The selective accumulation of such nanoparticles in atherosclerosis models in rabbits was shown 
by MRI [177]. 
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Fibrin is also a good target for atherosclerosis detection with IONPs. Using a thermal 
decomposition approach, Sepan et al. prepared iron oxide nanoparticles coated with specific functional 
groups of fibrin by the nanoemulsion method (Figure 9), obtaining a micelle-like nanostructure. These 
nanoparticles were tested using T1 weighted imaging, which is far much easier to identify  
in vivo [178]. 
Figure 9. Fibrin-specific IONPs for the T1-weighted imaging of fibrin in atherosclerotic 
plaque. Reproduced with permission from [178]. Copyright 2009, American  
Chemical Society. 
 
As a final example, we would like to highlight a recent contribution that makes use of one of the 
very well-known nanoparticles [179], IONPs coated with citric acid, which show selective 
accumulation in the calcifying microvesicles, characteristics of the atheroma lesion and also, to some 
extent, in the activated macrophages. All this makes these nanoparticles good candidates as probes for 
the study of the composition and inflammatory activity of the plaque at risk of destabilization. 
5. Conclusions 
The utility of nanotechnology in the study of cardiovascular diseases is currently fully demonstrated, 
from diagnosis to therapy. From the examples we have shown, it is clear that there are many examples 
of iron oxide-based particles able to diagnose and/or treat the atheroma plaque. For the next few years, 
the most difficult aspect that must be addressed is the applications of these nanoparticles in the clinic. 
For that to happen, one of the most important aspects is the development of reliable and reproducible 
methodologies allowing for the synthesis of the targeted nanoparticles we just saw. In our opinion, the 
best chances of achieving this goal is with the development of bio-orthogonal or chemo-selective 
approaches for the coupling of biologically-relevant compounds or drugs on the surface of IONPs. 
This kind of chemistry can deliver nano-compounds with controlled and specific composition on the 
surface. Moreover, it will allow for the binding of biomolecules with their intact native structure and 
function, assuring the best performance in terms of molecular imaging and disease treatment. This last 
point will also mean a clear advantage over the use of radionuclide-based probes for atherosclerosis, 
since, with a single radiation-free probe, the diagnosis, therapy and follow-up of the disease could be 
achieved. We consider that in the coming years, we will assist in the boom of this kind of 
functionalized nanoparticles in the field of cardiovascular imaging. 
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